Literature DB >> 15627212

Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.

Li Li1, Peter Reinhardt, Anita Schmitt, Thomas F E Barth, Jochen Greiner, Mark Ringhoffer, Hartmut Döhner, Markus Wiesneth, Michael Schmitt.   

Abstract

Recently, the focus is on new specific immunotherapies for AML such as cellular therapies employing dendritic cells (DCs) generated from AML blasts. AML-DCs express constitutionally leukemia-associated antigens (LAAs) present in AML blasts they are generated from. Here we investigated whether the generation of AML-DCs would alter the expression level of LAAs. Moreover, we evaluated the presence of HLA and costimulatory molecules on AML blasts versus AML-DCs. Quantitative real-time polymerase chain reaction (PCR) was performed for the following LAAs: preferentially expressed antigen in melanoma (PRAME), the receptor for hyaluronic acid mediated motility (RHAMM/CD168), Wilms' tumor gene 1 (WT-1) and proteinase 3. The expression of HLA-ABC, HLA-DR, CD40, CD80, CD83 and CD86 was evaluated by flow cytometry. RHAMM protein expression was evaluated by immunocytochemistry, recognition of AML-DCs by PRAME epitope-specific T cells was evaluated in a chromium-release assay. Quantitative real-time PCR for AML-DCs versus AML blasts showed an alteration in mRNA expression of LAAs. An elevated PCR signal for PRAME was detected in 7/12 AML-DC preparations. 6/12 AML-DC preparations showed a significant upregulation of the PCR signal for RHAMM. A stronger WT-1 and proteinase-3 signal was observed in PCR for only 2/12 and 1/12 AML-DCs , respectively. All preparations showed a strong expression of at least one of the LAAs examined. As demonstrated by flow cytometry, AML-DCs strongly upregulated costimulatory molecules like CD40 and CD80 in comparison with AML blasts. AML-DCs tested positive for RHAMM protein. PRAME positive AML-DCs were recognized by specific T cells. AML-DCs might constitute a powerful tool in immunotherapy for AML. Real-time PCR allows a quick and quantitative assessment of immunologically relevant LAA expression with only 10(5) DCs and might be helpful for the decision whether the AML-DC vaccination strategy is favourable or not.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15627212     DOI: 10.1007/s00262-004-0631-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

Review 1.  Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.

Authors:  Athalia R Pyzer; David E Avigan; Jacalyn Rosenblatt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  An autologous system for culturing head and neck squamous cell carcinomas for the assessment of cellular therapies on the chorioallantois membrane.

Authors:  S Gronau; B Thess; H Riechelmann; Y Fischer; A Schmitt; M Schmitt
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-10-27       Impact factor: 2.503

Review 3.  Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.

Authors:  Daniel Christoph Amberger; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-05       Impact factor: 3.747

4.  p38 Mitogen-Activated Protein Kinase in beryllium-induced dendritic cell activation.

Authors:  L Li; Z Huang; M Gillespie; P M Mroz; L A Maier
Journal:  Hum Immunol       Date:  2014-10-22       Impact factor: 2.850

5.  Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.

Authors:  Sebastian Ochsenreither; Ravindra Majeti; Thomas Schmitt; Derek Stirewalt; Ulrich Keilholz; Keith R Loeb; Brent Wood; Yongiae E Choi; Marie Bleakley; Edus H Warren; Michael Hudecek; Yoshiki Akatsuka; Irving L Weissman; Philip D Greenberg
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

Review 6.  Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.

Authors:  Nathalie Chaput; Stéphane De Botton; Michel Obeid; Lionel Apetoh; François Ghiringhelli; Theocharis Panaretakis; Caroline Flament; Laurence Zitvogel; Guido Kroemer
Journal:  J Mol Med (Berl)       Date:  2007-05-22       Impact factor: 4.599

7.  Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene.

Authors:  Monica Casucci; Serena Kimi Perna; Laura Falcone; Barbara Camisa; Zulma Magnani; Massimo Bernardi; Alessandro Crotta; Cristina Tresoldi; Katharina Fleischhauer; Maurilio Ponzoni; Silvia Gregori; Federico Caligaris Cappio; Fabio Ciceri; Claudio Bordignon; Alessandro Cignetti; Attilio Bondanza; Chiara Bonini
Journal:  Mol Ther       Date:  2012-11-13       Impact factor: 11.454

8.  Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia.

Authors:  M Wemeau; O Kepp; A Tesnière; T Panaretakis; C Flament; S De Botton; L Zitvogel; G Kroemer; N Chaput
Journal:  Cell Death Dis       Date:  2010-12-02       Impact factor: 8.469

9.  Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.

Authors:  R Casalegno-Garduño; C Meier; A Schmitt; A Spitschak; I Hilgendorf; S Rohde; C Hirt; M Freund; B M Pützer; M Schmitt
Journal:  Clin Dev Immunol       Date:  2012-06-06

Review 10.  Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.

Authors:  Joseph Cannova; Peter Breslin S J; Jiwang Zhang
Journal:  Front Med       Date:  2015-08-22       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.